Regenxbio Inc (RGNX)
9.63
-1.51
(-13.55%)
USD |
NASDAQ |
Nov 15, 16:00
9.97
+0.34
(+3.53%)
After-Hours: 20:00
Regenxbio Research and Development Expense (TTM): 213.82M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 213.82M |
| June 30, 2024 | 217.58M |
| March 31, 2024 | 228.59M |
| December 31, 2023 | 232.27M |
| September 30, 2023 | 239.09M |
| June 30, 2023 | 244.22M |
| March 31, 2023 | 245.34M |
| December 31, 2022 | 242.45M |
| September 30, 2022 | 227.93M |
| June 30, 2022 | 212.47M |
| March 31, 2022 | 197.34M |
| December 31, 2021 | 181.44M |
| September 30, 2021 | 180.64M |
| June 30, 2021 | 176.75M |
| March 31, 2021 | 168.98M |
| December 31, 2020 | 166.29M |
| September 30, 2020 | 152.92M |
| June 30, 2020 | 144.64M |
| March 31, 2020 | 136.02M |
| Date | Value |
|---|---|
| December 31, 2019 | 124.18M |
| September 30, 2019 | 114.71M |
| June 30, 2019 | 97.52M |
| March 31, 2019 | 89.53M |
| December 31, 2018 | 83.87M |
| September 30, 2018 | 73.71M |
| June 30, 2018 | 67.72M |
| March 31, 2018 | 60.16M |
| December 31, 2017 | 57.22M |
| September 30, 2017 | 59.11M |
| June 30, 2017 | 59.16M |
| March 31, 2017 | 55.92M |
| December 31, 2016 | 45.48M |
| September 30, 2016 | 34.23M |
| June 30, 2016 | 27.34M |
| March 31, 2016 | 20.67M |
| December 31, 2015 | 17.28M |
| September 30, 2015 | 14.56M |
| June 30, 2015 | 9.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
124.18M
Minimum
Dec 2019
245.34M
Maximum
Mar 2023
196.65M
Average
204.90M
Median
Research and Development Expense (TTM) Benchmarks
| Catalyst Pharmaceuticals Inc | 10.82M |
| EyePoint Pharmaceuticals Inc | 107.45M |
| Cassava Sciences Inc | 67.84M |
| Vertex Pharmaceuticals Inc | 3.456B |
| Sarepta Therapeutics Inc | 800.09M |